Vectus Biosystems Limited (VBS:ASX)


right-arrow Created with Sketch. 0 (0%)
MCAP $35.45M
Last trade 16.12pm 13/04/2021 20mins delayed

Latest Announcements

26/02/2021 Price SensitivePSVBSVectus Biosystems Limited
29/01/2021 Price SensitivePSVBSVectus Biosystems Limited
07/12/2020VBSVectus Biosystems Limited
30/11/2020VBSVectus Biosystems Limited
30/11/2020VBSVectus Biosystems Limited
20/11/2020 Price SensitivePSVBSVectus Biosystems Limited
20/11/2020 Price SensitivePSVBSVectus Biosystems Limited
19/11/2020 Price SensitivePSVBSVectus Biosystems Limited

Company Overview

Vectus Biosystems Limited is engaged in medical Research and Development. The Company's drug candidates can be orally administered. The Company's primary lead compound, VB0004, has been shown to be both anti-hypertensive and anti-fibrotic in the heart and kidneys. Using its platform technology, the Company has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. It also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH), as well as pulmonary fibrotic diseases. Accugen is a platform, developed by the Company's subsidiary, Accugen Pty Limited. Accugen comprises reagents and software that quantitate quantitative polymerase chain reaction (qPCR) reactions, which measures the amount of Deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) in a sample. It identifies drug targets with specific activity in the heart, kidneys, lungs and liver.

VBS in the news

Search Previous Announcements